Transition's drug discovery platform is a patented technology which identifies and optimizes lead compounds in about six months which is considerably less time than industry standards. The speed, accuracy and flexibility of this technology has been validated through the successful completion of multiple screening studies for large pharmaceutical companies across a wide variety of drug targets. This technology positions Transition to effectively compete with large pharmaceutical and biotech companies for the development of therapeutics to validated disease targets.

Discovery Program for High Value Lead Compounds

With the pharmaceutical industry's increasing demand for new products, there is a premium for specific classes of lead candidates targeting high-value drug targets. Transition has a program identifying lead compounds to five of the most sought-after drug targets in clinical development today, focusing on large indications such as Hypertension, Anemia, and Alzheimer's disease. Products inhibiting these drug targets have the potential to provide significant benefit over currently marketed multi- billion-dollar therapeutics.